Review of tadalafil in the treatment of erectile dysfunction

Author: Meuleman E.J.

Source: Expert Opinion on Pharmacotherapy, Volume 4, Number 11, 1 November 2003 , pp. 2049-2056(8)

Publisher: Informa Healthcare

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Approximately 150 million men worldwide experience erectile dysfunction (ED) whereby they are unable to achieve and maintain an erection adequate for satisfactory sexual performance. ED has a considerable impact on quality of life. Tadalafil (Cialis™, Eli Lilly & Co./ICOS) is a novel effective and safe phosphodiesterase type 5 inhibitor, a secondary messenger for the smooth muscle relaxing effects of nitric oxide, which plays a central role in the vasodilation of erectile tissues. It has a longer half-life than sildenafil. As head-to-head comparative trials are lacking, it is not clear what tadalafil offers over sildenafil. In terms of marketing, much is made of the ‘spontaneity’ achievable because of the (relatively) longer half-life of tadalafil.

Keywords: erectile dysfunction; phosphodiesterase type 5 inhibition; tadalafil; treatment

Document Type: Drug Evaluation

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$96.00 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A